Contrasting Milestone Pharmaceuticals (NASDAQ:MIST) and Ovid Therapeutics (NASDAQ:OVID)

Milestone Pharmaceuticals (NASDAQ:MIST) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Ovid Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55 million	58.64	-$63.06 million	($0.69)	-1.06
Ovid Therapeutics	$7.25 million	68.42	-$17.41 million	($0.31)	-8.19

Ovid Therapeutics has higher revenue and earnings than Milestone Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Milestone Pharmaceuticals and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Ovid Therapeutics	N/A	-23.64%	-20.52%

Analyst Ratings

This is a breakdown of recent ratings for Milestone Pharmaceuticals and Ovid Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1	1	4	1	2.71
Ovid Therapeutics	1	0	11	1	2.92

Milestone Pharmaceuticals presently has a consensus target price of $6.40, indicating a potential upside of 776.71%. Ovid Therapeutics has a consensus target price of $6.00, indicating a potential upside of 136.22%. Given Milestone Pharmaceuticals’ higher probable upside, research analysts clearly believe Milestone Pharmaceuticals is more favorable than Ovid Therapeutics.

Volatility and Risk

Milestone Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500.

Summary

Ovid Therapeutics beats Milestone Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.